Frontiers in Immunology (Feb 2021)
Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics
- Loic Ysebaert,
- Loic Ysebaert,
- Loic Ysebaert,
- Loic Ysebaert,
- Loic Ysebaert,
- Loic Ysebaert,
- Loic Ysebaert,
- Anne Quillet-Mary,
- Anne Quillet-Mary,
- Anne Quillet-Mary,
- Anne Quillet-Mary,
- Anne Quillet-Mary,
- Anne Quillet-Mary,
- Marie Tosolini,
- Marie Tosolini,
- Marie Tosolini,
- Marie Tosolini,
- Marie Tosolini,
- Marie Tosolini,
- Frederic Pont,
- Frederic Pont,
- Camille Laurent,
- Camille Laurent,
- Camille Laurent,
- Camille Laurent,
- Camille Laurent,
- Camille Laurent,
- Camille Laurent,
- Jean-Jacques Fournié,
- Jean-Jacques Fournié,
- Jean-Jacques Fournié,
- Jean-Jacques Fournié,
- Jean-Jacques Fournié,
- Jean-Jacques Fournié
Affiliations
- Loic Ysebaert
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France
- Loic Ysebaert
- Toulouse University, Toulouse, France
- Loic Ysebaert
- ERL 5294 CNRS, Toulouse, France
- Loic Ysebaert
- Institut Universitaire du Cancer-Oncopole, Toulouse, France
- Loic Ysebaert
- Laboratoire d’Excellence ‘TOUCAN’, Toulouse, France
- Loic Ysebaert
- Institut Carnot Lymphome CALYM, Lyon, France
- Loic Ysebaert
- Service d’Hématologie, CHU Toulouse, Toulouse, France
- Anne Quillet-Mary
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France
- Anne Quillet-Mary
- Toulouse University, Toulouse, France
- Anne Quillet-Mary
- ERL 5294 CNRS, Toulouse, France
- Anne Quillet-Mary
- Institut Universitaire du Cancer-Oncopole, Toulouse, France
- Anne Quillet-Mary
- Laboratoire d’Excellence ‘TOUCAN’, Toulouse, France
- Anne Quillet-Mary
- Institut Carnot Lymphome CALYM, Lyon, France
- Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France
- Marie Tosolini
- Toulouse University, Toulouse, France
- Marie Tosolini
- ERL 5294 CNRS, Toulouse, France
- Marie Tosolini
- Institut Universitaire du Cancer-Oncopole, Toulouse, France
- Marie Tosolini
- Laboratoire d’Excellence ‘TOUCAN’, Toulouse, France
- Marie Tosolini
- Institut Carnot Lymphome CALYM, Lyon, France
- Frederic Pont
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France
- Frederic Pont
- Institut Carnot Lymphome CALYM, Lyon, France
- Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France
- Camille Laurent
- Toulouse University, Toulouse, France
- Camille Laurent
- ERL 5294 CNRS, Toulouse, France
- Camille Laurent
- Institut Universitaire du Cancer-Oncopole, Toulouse, France
- Camille Laurent
- Laboratoire d’Excellence ‘TOUCAN’, Toulouse, France
- Camille Laurent
- Institut Carnot Lymphome CALYM, Lyon, France
- Camille Laurent
- Laboratoire d’anatomo-pathologie, CHU Toulouse, Toulouse, France
- Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France
- Jean-Jacques Fournié
- Toulouse University, Toulouse, France
- Jean-Jacques Fournié
- ERL 5294 CNRS, Toulouse, France
- Jean-Jacques Fournié
- Institut Universitaire du Cancer-Oncopole, Toulouse, France
- Jean-Jacques Fournié
- Laboratoire d’Excellence ‘TOUCAN’, Toulouse, France
- Jean-Jacques Fournié
- Institut Carnot Lymphome CALYM, Lyon, France
- DOI
- https://doi.org/10.3389/fimmu.2021.597651
- Journal volume & issue
-
Vol. 12
Abstract
High-definition transcriptomic studies through single-cell RNA sequencing (scRNA-Seq) have revealed the heterogeneity and functionality of the various microenvironments across numerous solid tumors. Those pioneer studies have highlighted different cellular signatures correlated with clinical response to immune checkpoint inhibitors. scRNA-Seq offers also a unique opportunity to unravel the intimate heterogeneity of the ecosystems across different lymphoma entities. In this review, we will first cover the basics and future developments of the technology, and we will discuss its input in the field of translational lymphoma research, from determination of cell-of-origin and functional diversity, to monitoring of anti-cancer targeted drugs response and toxicities, and how new improvements in both data collection and interpretation will further foster precision medicine in the upcoming years.
Keywords
- single-cell RNA sequencing (scRNA-seq)
- lymphoma
- microenvironment
- bioinformatics analysis
- cell of origin (COO)